GEN Exclusives

More »

GEN News Highlights

More »
Dec 18, 2012

Oncodesign and LNGT Enter Research Collaboration with Ipsen for Parkinson's Disease

  • Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the KU Leuven entered a research collaboration to evaluate, with Ipsen, Oncodesign’s compounds in multiple pharmacology models for Parkinson's disease. The deal builds on Oncodesign's LRRK2 program with advanced Nanocyclix® lead molecules that was partnered with Ipsen in January 2012.

    Under the terms of the agreement, Oncodesign and LNGT will closely collaborate to advance Oncodesign's Parkinson’s disease program toward clinical development. LNGT will receive full financial support from Oncodesign for these activities.

    In January, Ipsen and Oncodesign partnered for the development of new therapeutic agents against LRKK2 involved in Parkinson's disease, with focus in neurology and movement disorders. The partnership was founded on LLRK2 inhibitors originating from Oncodesign’s Nanocyclix medicinal chemistry technology for developing kinase inhibitor leads. Ipsen retained two options to exclusively license Oncodesign’s LRRK2 inhibitor program for worldwide development and commercialization, on the achievement of clinical proof-of-concept.

    “Our partnership with Ipsen on the discovery of novel therapeutic agents in Parkinson’s disease has advanced to a stage where we can use further in depth expertise and advanced pharmacology models to position our leads,” said Jan Hoflack, Ph.D., CSO and head of Oncodesign's discovery activities.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?